Intercept rallies ahead of conference, BofA defends lofty target

Investors will be watching Intercept Pharmaceuticals (ICPT) closely today after a wild ride during the last four trading sessions.

The company is set to present at the JPMorgan Healthcare Conference at 10:30 ET. Here's TheStreet's Adam Feuerstein: "[It's] going to be an adventure."

Meanwhile, BofA's Rachel McMinn (who caused a stir by putting an $872 price target on the shares last week) is out in defense of the stock, which has fallen over the past two days.

Ultimately, McMinn thinks investors need to be patient, given OCA's potential.

ICPT +7% premarket

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs